# Anuh Pharma (NSE: ANUHPHR) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ANUHPHR · Pivot · prices to 22 Oct 2026

Anuh Pharma (NSE: ANUHPHR) closed at ₹80.29 on 22 Oct 2026, up 0.68% on the day. With a market capitalisation of ₹805 Cr, it ranks 1562nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 19.6× trailing earnings, against a return on equity of 14.5% in FY25. Over the past year the share price has risen 0.4%. Its 52-week range is ₹67.00 (30 Mar 2026) to ₹99.50 (8 Sep 2026); the last close is 19.3% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹202 Cr (+2.0% year on year) and net profit ₹12 Cr (−6.3%), on a standalone basis. Promoters held 71.80% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹80.29 |
| Market cap | ₹805 Cr |
| P/E (trailing) | 19.6 |
| ROE | 14.5% (FY25) |
| ROCE | 18.8% (FY25) |
| Debt to equity | 0.03 |
| 52-week high | ₹99.50 (8 Sep 2026) |
| 52-week low | ₹67.00 (30 Mar 2026) |
| 1-year return | +0.4% |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹202 Cr | +2.0% | ₹12 Cr | −6.3% | ₹1.17 |
| Q3 FY26 | ₹197 Cr | +23.6% | ₹13 Cr | +30.1% | ₹1.34 |
| Q2 FY26 | ₹186 Cr | +12.0% | ₹8 Cr | −49.4% | ₹0.76 |
| Q1 FY26 | ₹186 Cr | +35.2% | ₹8 Cr | −12.7% | ₹1.66 |
| Q4 FY25 | ₹198 Cr | +20.9% | ₹12 Cr | −18.9% | ₹2.49 |
| Q3 FY25 | ₹160 Cr | −7.3% | ₹10 Cr | −45.9% | ₹2.06 |
| Q2 FY25 | ₹166 Cr | +11.0% | ₹15 Cr | +8.7% | ₹3.00 |
| Q1 FY25 | ₹138 Cr | −14.6% | ₹10 Cr | −19.1% | ₹1.90 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹662 Cr | ₹47 Cr |
| FY24 | ₹647 Cr | ₹60 Cr |
| FY23 | ₹527 Cr | ₹36 Cr |
| FY22 | ₹487 Cr | ₹31 Cr |
| FY21 | ₹432 Cr | ₹28 Cr |
| FY20 | ₹307 Cr | ₹14 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 71.80%
- Foreign institutions: 0.01%
- Domestic institutions: 0.00%
- Non-institutions: 28.19%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Themis Medicare](https://app.pivotnow.in/stock/THEMISMED) | ₹98.08 | ₹903 Cr | — | — |
| [Shree Ganesh Re](https://app.pivotnow.in/stock/SGRL) | ₹658.25 | ₹845 Cr | 47.7 | — |
| [Kilitch Drugs (India)](https://app.pivotnow.in/stock/KILITCH) | ₹215.00 | ₹752 Cr | 24.2 | — |
| [Vikram Thermo](https://app.pivotnow.in/stock/VIKRAMTH) | — | ₹728 Cr | — | — |
| [Zim Laboratories](https://app.pivotnow.in/stock/ZIMLAB) | ₹133.50 | ₹715 Cr | 112.2 | — |
| [Valiant Laboratories](https://app.pivotnow.in/stock/VALIANTLAB) | ₹131.05 | ₹712 Cr | — | — |

## Questions and answers

### What is the share price of Anuh Pharma today?

Anuh Pharma (NSE: ANUHPHR) last closed at ₹80.29 on 22 Oct 2026. Its 52-week high is ₹99.50 and its 52-week low is ₹67.00.

### What is the market cap of Anuh Pharma?

Anuh Pharma's market capitalisation is ₹805 Cr (₹805 Cr) at the 22 Oct 2026 close, ranking 1562nd among the NSE companies Pivot tracks.

### What is the P/E ratio of Anuh Pharma?

Anuh Pharma trades at a trailing P/E of 19.6. The median P/E of the 3 closest Pharma & Healthcare peers by market cap is 47.7.

### What is the ROE and ROCE of Anuh Pharma?

Return on equity was 14.5% in FY25 and return on capital employed was 18.8% in FY25 (standalone figures).

### Is Anuh Pharma a debt-free company?

Anuh Pharma is close to debt-free: its debt-to-equity ratio was 0.03 in FY25.

### What were Anuh Pharma's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Anuh Pharma reported revenue of ₹202 Cr, +2.0% year on year, and net profit of ₹12 Cr, −6.3% year on year.

### How has Anuh Pharma stock performed over the last year?

Anuh Pharma's share price has risen 0.4% over the past year, +0.5% over three months and −15.4% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Anuh Pharma?

As of 30 Jun 2026: promoters 71.80%, foreign institutions 0.01%, domestic institutions 0.00%, non-institutions 28.19%.

### Who are Anuh Pharma's competitors?

The listed Pharma & Healthcare companies closest to Anuh Pharma by market cap are Themis Medicare, Shree Ganesh Re, Kilitch Drugs (India), Vikram Thermo, Zim Laboratories and Valiant Laboratories.

### Is Anuh Pharma a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Anuh Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ANUHPHR against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.